Tirzepatide in Metabolically Dysfunctional-Associated Steatohepatitis (MASH): A Bibliometric and Evidence-Based Review.
Tirzepatide is turning heads in metabolic liver disease research, especially for those tackling metabolically dysfunctional-associated steatohepatitis (MASH). A new review out of Transilvania University digs deep into both the clinical evidence and research trends around this dual GIP/GLP-1 receptor agonist. The verdict is clear: tirzepatide isn’t just hype — it’s changing the conversation on MASH.
J Diabetes Res
by Pantea I, Repanovici A
“Tirzepatide in Metabolically Dysfunctional-Associated Steatohepatitis (MASH): A Bibliometric and Evidence-Based Review. Pantea I(1), Repanovici A(1). Author information: (1)Transilvania University of Brasov, Brasov, Romania, unitbv.ro. PURPOSE: Metabolically-dysfunction-associated steatohepatitis (MASH) is the progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD) and is strongly linked to obesity and type 2 diabetes mellitus (T2D). Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a promising therapeutic option due to its profound metabolic effects and potential hepatic benefits. This study integrates bibliometric mapping with current clinical evidence to evaluate tirzepatide's role in MASLD/MASH. METHODS: A bibliometric search was conducted in the Web of Science Core Collection (2018-2025) using predefined keywords related to tirzepatide and metabolic liver disease. Twenty-five full-text publications-including randomized controlled trials, post hoc analyses, meta-analyses, mechanistic reviews, and international guidelines-were systematically reviewed. Co-occurrence networks were generated using VOSviewer. RESULTS: Scientific output on tirzepatide and MASLD/MASH has increased rapidly since 2020, with thematic clusters centered on metabolic regulation, hepatic inflammation, and fibrosis. Clinical evidence shows that tirzepatide induces substantial weight loss, improves glycaemic control, and reduces hepatic biomarkers such as ALT, AST, K 18, and Pro C3. The SYNERGY-nonalcoholic steatohepatitis (NASH) trial demonstrated high rates of MASH resolution without fibrosis worsening and meaningful fibrosis regression at 52 weeks. Network meta-analyses position tirzepatide among the most effective therapies currently available. Recent EASL-EASD-EASO guidelines recommend tirzepatide for MASLD patients with obesity, T2D, or cardiometabolic risk. CONCLUSIONS: Tirzepatide combines potent metabolic effects with significant hepatic improvements, positioning it as a promising therapy for MASLD/MASH. Although long-term and phase III data are still needed, current evidence supports tirzepatide as a key component of modern metabolic liver disease management. Copyright © 2026 Ileana Pantea and Angela Repanovici. Journal of Diabetes Research published by John Wiley & Sons Ltd.”
Here’s the big picture. Scientific papers on tirzepatide and MASH have exploded since 2020. Researchers are zeroing in on three targets: metabolic regulation, liver inflammation, and fibrosis. The clinical evidence keeps stacking up. Trials and meta-analyses show tirzepatide leads to major weight loss, better glucose control, and big drops in liver biomarkers like ALT, AST, K18, and Pro C3. That’s not just numbers on a chart — it means real changes in the metabolic and hepatic profile of research subjects.
The SYNERGY-NASH trial is a standout. Key takeaway: tirzepatide drove high rates of MASH resolution without making fibrosis worse, and even improved fibrosis for many after just 52 weeks. Network meta-analyses now rank tirzepatide among the most effective research compounds for MASLD and MASH.
Tirzepatide slashed liver enzymes and fibrosis markers
Researchers saw meaningful weight loss and glycemic improvement
EASL-EASD-EASO guidelines now recommend tirzepatide for MASLD patients with obesity, T2D, or cardiometabolic risk
The research community is moving fast, but they're also calling for longer-term and phase III data to really lock in tirzepatide’s profile. For now, it’s clear this peptide is a key player in metabolic liver disease studies. Read up on the science or check sourcing options in the tirzepatide library and the vendor directory. This is one to watch.
Related Reading
Weight-Loss Drugs: What You Must Know Before Taking Semaglutide or Tirzepatide
News · Can J DiabetesOral Health Considerations and Dental Management Guidelines for Semaglutide Medications.
News · Anim Sci JNutritional Endocrinology in Dairy Cattle: Roles of the Ghrelin and Glucagon-Like Peptide Axis in Metabolic Adaptation and Developmental Programming.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.